ASGR1 and liver cancer: RNA nanotechnology-modified galactosamine (GalNAc)-decorated Exos have served as an effective means for targeted delivery to liver cancer, as GalNAc binds to the overexpressed asialoglycoprotein receptor (ASGP-R) on liver cancer cells, endowing the Exos with targeting capability (172).